Inforsense and idbs link up on Translational Research

Inforsense and idbs held a Translational Research Symposium yesterday morning at the Dali Museum on the south bank in London. They are impressive with the same aims as Microsoft, to provide supporting integrated databases for all healthcare systems, with one user interface. Their advantage is that they really understand the pharma industry and work with academic and medical teams outside industry.
This creative team are looking at the problem differently - to put in place a means to draw from data in multiple environments and be able to interogate it through one interface. They understand the issues that lie between research based data and medically derived data - we all know this interface must be made seamless so that we can use research based technology in the clinic. This will enable more responsive clinical trials and should reduce unit cost and irrelevant activities. Amongst the speakers were those who understand the change required in clinical research and who speak eloquently about the defining features of a good biomarker that will support changes in clinical protocol design. A good day, Inforsense and idbs - thank you. go to this website to find out more...
http://www.idbs.com/InforSenseSuite/TranslationalResearchSolution/
Speakers on 22nd Oct were:
Professor Simon Lovestone, Institute of Psychiatry, King's College, London
Professor Richard Begent, Cancer research UK Targeting and Imaging group, Dept of Oncology, UCL Cancer Institute, London
Dr Andrew Chadwick and Tom Parke from Tessella
Dr Anita Grigoriadis, Breakthrough Breast cancer translational research at Guys
Jonathan Sheldon, Director, technology Solutions, Inforsense.
Idbs Chairman and CEO , Neil Kipling hosted the event.

Steve Lohr supporting the case for the changing pharma model

The Future of Healthcare Technology Summit

This two day summit in Boston's MIT Faculty Club showed a future world where complexity will be unravelled and presented to us as an aid to our jobs. Whether an emergency room medic, or a drug discovery scientist, information technology will be available to inform our decision making in real time, not removing our discretion but guiding us to the possibilities and most likely scenarios we face.
Robots that influence us to take care of ourselves, help us diet and motivate those in need of support to help themselves with their medications. Headsets that inform about the most likely condition of a trauma patient as the medic inputs vital signs and responds to questions - guiding the clinician to perform the most likely to be useful and informative tests rather than waste money on cautionary but uninformative ones. Programmes to integrate social, environmental and medical influences on our lives to predict disease propensity and to change behaviour to avoid disease onset and Microsoft's new methodology to compute huge volumes of input data, regardless of source that can be interogated to provide us with key connections between key points of reference (genetic sequence, proteins, medicines, side effects - you name it!).